- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Annual Issues
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Reviewers Acknowledgment
- Submit a Manuscript
- Subscription Information
- Table of Contents
Journal of Biomedicine and Biotechnology
Volume 2012 (2012), Article ID 180363, 9 pages
Mechanism of Growth Inhibition of Prostate Cancer Xenografts by Valproic Acid
1James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Marburg 205A, 600 North Wolfe Street, Baltimore, MD 21287, USA
2Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA
3Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Received 20 May 2012; Revised 16 July 2012; Accepted 17 July 2012
Academic Editor: Eric W. Lam
Copyright © 2012 Abhinav Sidana et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- A. Rephaeli, D. Blank-Porat, N. Tarasenko et al., “In vivo and in vitro antitumor activity of butyroyloxymethyl-diethyl phosphate (AN-7), a histone deacetylase inhibitor, in human prostate cancer,” International Journal of Cancer, vol. 116, no. 2, pp. 226–235, 2005.
- P. A. Konstantinopoulos, M. V. Karamouzis, and A. G. Papavassiliou, “Focus on acetylation: the role of histone deacetylase inhibitors in cancer therapy and beyond,” Expert Opinion on Investigational Drugs, vol. 16, no. 5, pp. 569–571, 2007.
- M. Dokmanovic and P. A. Marks, “Prospects: histone deacetylase inhibitors,” Journal of Cellular Biochemistry, vol. 96, no. 2, pp. 293–304, 2005.
- Y. Sowa, T. Orita, S. Hiranabe-Minamikawa et al., “Histone deacetylase inhibitor activates the p21/WAF1/Cip1 gene promoter through the Sp1 sites,” Annals of the New York Academy of Sciences, vol. 886, pp. 195–199, 1999.
- M. V. Blagosklonny, “Are p27 and p21 cytoplasmic oncoproteins?” Cell Cycle (Georgetown, Tex.), vol. 1, no. 6, pp. 391–393, 2002.
- M. Göttlicher, S. Minucci, P. Zhu et al., “Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells,” The EMBO Journal, vol. 20, no. 24, pp. 6969–6978, 2002.
- Q. Xia, J. Sung, W. Chowdhury et al., “Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo,” Cancer Research, vol. 66, no. 14, pp. 7237–7244, 2006.
- S. Shabbeer, M. S. Q. Kortenhorst, S. Kachhap, N. Galloway, R. Rodriguez, and M. A. Carducci, “Multiple molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo,” Prostate, vol. 67, no. 10, pp. 1099–1110, 2007.
- C.-L. Chen, J. Sung, M. Cohen et al., “Valproic acid inhibits invasiveness in bladder cancer but not in prostate cancer cells,” Journal of Pharmacology and Experimental Therapeutics, vol. 319, no. 2, pp. 533–542, 2006.
- D. M. Turnbull, M. D. Rawlins, D. Weightman, and D. W. Chadwick, “Plasma concentrations of sodium valproate: their clinical value,” Annals of Neurology, vol. 14, no. 1, pp. 38–42, 1983.
- S. Zha, W. R. Gage, J. Sauvageot et al., “Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma,” Cancer Research, vol. 61, no. 24, pp. 8617–8623, 2001.
- S. Manley, N. R. Mucci, A. M. De Marzo, and M. A. Rubin, “Relational database structure to manage high-density tissue microarray data and images for pathology studies focusing on clinical outcome the prostate specialized program of research excellence model,” American Journal of Pathology, vol. 159, no. 3, pp. 837–843, 2001.
- D. A. Faith, W. B. Isaacs, J. D. Morgan et al., “Trefoil factor 3 overexpression in prostatic carcinoma: prognostic importance using tissue microarrays,” Prostate, vol. 61, no. 3, pp. 215–227, 2004.
- A. M. De Marzo, B. Knudsen, K. Chan-Tack, and J. I. Epstein, “E-cadherin expression as a marker of tumor aggressiveness in routinely processed radical prostatectomy specimens,” Urology, vol. 53, no. 4, pp. 707–713, 1999.
- C. Marshall, “How do small GTPase signal transduction pathways regulate cell cycle entry?” Current Opinion in Cell Biology, vol. 11, no. 6, pp. 732–736, 1999.
- J. R. Alt, A. B. Gladden, and J. A. Diehl, “p21Cip1 promotes cyclin D1 nuclear accumulation via direct inhibition of nuclear export,” The Journal of Biological Chemistry, vol. 277, no. 10, pp. 8517–8523, 2002.
- W. K. Schlage, H. Bülles, D. Friedrichs, M. Kuhn, A. Teredesai, and P. M. Terpstra, “Cytokeratin expression patterns in the rat respiratory tract as markers of epithelial differentiation in inhalation toxicology. II. Changes in cytokeratin expression patterns following 8-day exposure to room-aged cigarette sidestream smoke,” Toxicologic Pathology, vol. 26, no. 3, pp. 344–360, 1998.
- Y. Wang, S. W. Hayward, M. Cao, K. A. Thayer, and G. R. Cunha, “Cell differentiation lineage in the prostate,” Differentiation, vol. 68, no. 4-5, pp. 270–279, 2001.
- G. Schaller, I. Fuchs, W. Pritze et al., “Elevated keratin 18 protein expression indicates a favorable prognosis in patients with breast cancer,” Clinical Cancer Research, vol. 2, no. 11, pp. 1879–1885, 1996.
- A. F. Santos, H. Huang, and D. J. Tindall, “The androgen receptor: a potential target for therapy of prostate cancer,” Steroids, vol. 69, no. 2, pp. 79–85, 2004.
- V. Ananthanarayanan, R. J. Deaton, X. J. Yang, M. R. Pins, and P. H. Gann, “Alteration of proliferation and apoptotic markers in normal and premalignant tissue associated with prostate cancer,” BMC Cancer, vol. 6, article 73, 2006.
- L. Fina, H. V. Molgaard, D. Robertson et al., “Expression of the CD34 gene in vascular endothelial cells,” Blood, vol. 75, no. 12, pp. 2417–2426, 1990.
- E. Yildiz, S. Ayan, F. Goze, G. Gokce, and E. Y. Gultekin, “Relation of microvessel density with microvascular invasion, metastasis and prognosis in renal cell carcinoma,” BJU International, vol. 101, no. 6, pp. 758–764, 2008.
- T. Liu, S. Kuljaca, A. Tee, and G. M. Marshall, “Histone deacetylase inhibitors: multifunctional anticancer agents,” Cancer Treatment Reviews, vol. 32, no. 3, pp. 157–165, 2006.
- R. R. Rosato and S. Grant, “Histone deacetylase inhibitors: insights into mechanisms of lethality,” Expert Opinion on Therapeutic Targets, vol. 9, no. 4, pp. 809–824, 2005.
- L. C. Sambucetti, D. D. Fischer, S. Zabludoff et al., “Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects,” The Journal of Biological Chemistry, vol. 274, no. 49, pp. 34940–34947, 1999.
- S. Iwata, T. Saito, Y. Ito et al., “Antitumor activities of valproic acid on Epstein-Barr virus-associated T and natural killer lymphoma cells,” Cancer Science, vol. 103, no. 2, pp. 375–381, 2012.
- A. Kuendgen and N. Gattermann, “Valproic acid for the treatment of myeloid malignancies,” Cancer, vol. 110, no. 5, pp. 943–954, 2007.
- M. Ocker and R. Schneider-Stock, “Histone deacetylase inhibitors: signalling towards p21cip1/waf1,” International Journal of Biochemistry and Cell Biology, vol. 39, no. 7-8, pp. 1367–1374, 2007.
- W. Li, A. Sanki, R. Z. Karim et al., “The role of cell cycle regulatory proteins in the pathogenesis of melanoma,” Pathology, vol. 38, no. 4, pp. 287–301, 2006.
- J. Bartek, J. Bartkova, and J. Lukas, “The retinoblastoma protein pathway and the restriction point,” Current Opinion in Cell Biology, vol. 8, no. 6, pp. 805–814, 1996.
- D. Parry, D. Mahony, K. Wills, and E. Lees, “Cyclin D-CDK subunit arrangement is dependent on the availability of competing INK4 and p21 class inhibitors,” Molecular and Cellular Biology, vol. 19, no. 3, pp. 1775–1783, 1999.
- B. Willipinski-Stapelfeldt, S. Riethdorf, V. Assmann et al., “Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells,” Clinical Cancer Research, vol. 11, no. 22, pp. 8006–8014, 2005.
- P. A. Marks, V. M. Richon, and R. A. Rifkind, “Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells,” Journal of the National Cancer Institute, vol. 92, no. 15, pp. 1210–1216, 2000.
- J. T. Isaacs and W. B. Isaacs, “Androgen receptor outwits prostate cancer drugs,” Nature Medicine, vol. 10, no. 1, pp. 26–27, 2004.
- I. U. Ali, D. R. Senger, and L. E. H. Smith, “Angiogenesis as a potential biomarker in prostate cancer chemoprevention trials,” Urology, vol. 57, no. 4, pp. 143–147, 2001.
- R. O. Schlingemann, F. J. R. Rietveld, R. M. W. De Waal et al., “Leukocyte antigen CD34 is expressed by a subset of cultured endothelial cells and on endothelial abluminal microprocesses in the tumor stroma,” Laboratory Investigation, vol. 62, no. 6, pp. 690–696, 1990.
- E. Sabo, A. Boltenko, Y. Sova, A. Stein, S. Kleinhaus, and M. B. Resnick, “Microscopic analysis and significance of vascular architectural complexity in renal cell carcinoma,” Clinical Cancer Research, vol. 7, no. 3, pp. 533–537, 2001.